Rhumbline Advisers Boosts Stock Position in argenx SE (NASDAQ:ARGX)

Rhumbline Advisers increased its position in shares of argenx SE (NASDAQ:ARGX) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,608 shares of the company’s stock after buying an additional 66 shares during the quarter. Rhumbline Advisers’ holdings in argenx were worth $2,219,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Advisors Preferred LLC purchased a new stake in argenx in the fourth quarter valued at approximately $73,000. GAMMA Investing LLC increased its position in shares of argenx by 44.8% during the fourth quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock worth $155,000 after acquiring an additional 78 shares during the period. SG Americas Securities LLC raised its stake in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares in the last quarter. Fulton Bank N.A. purchased a new position in argenx in the fourth quarter valued at $226,000. Finally, Keudell Morrison Wealth Management purchased a new position in argenx in the third quarter worth approximately $207,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ARGX shares. Wells Fargo & Company boosted their target price on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday. Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday. William Blair reissued an “outperform” rating on shares of argenx in a report on Friday. JPMorgan Chase & Co. increased their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Finally, JMP Securities increased their price objective on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $661.17.

argenx Stock Down 0.3 %

Shares of argenx stock opened at $622.61 on Tuesday. The business has a fifty day simple moving average of $642.62 and a 200-day simple moving average of $591.22. The firm has a market cap of $37.83 billion, a price-to-earnings ratio of -707.51 and a beta of 0.58. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.